Amanda M DiBattista1, Sonya B Dumanis1, Joshua Newman1, G William Rebeck2. 1. Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA. 2. Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA. Electronic address: gwr2@georgetown.edu.
Abstract
BACKGROUND: Over 70 million Americans inherit the strongest genetic risk factor for Alzheimer's disease (AD), apolipoprotein E4 (APOE4), but have no course for reducing their risk. The association of non-steroidal anti-inflammatory drug (NSAID) use with reduced risk of AD for APOE4-carriers suggests that NSAIDs may be useful in AD prevention. METHODS: We identified phenotypes associated with APOE4 in APOE knock-in mice in order to define modifiable measures that correlate with risk of AD. RESULTS: APOE4 mouse brains showed altered post-translational modifications and biochemical distribution of APOE compared to APOE3 mice; these differences were also observed in brains of human APOE4 carriers. Two-month treatment with ibuprofen significantly altered the expression pattern of APOE in APOE4 mice to that of APOE3 mice; PPAR-γ agonist pioglitazone also had a significant effect. APOE4 mice also show deficits in dendritic spine density, and ibuprofen and pioglitazone significantly increased dendritic spine density. CONCLUSIONS: We report new phenotypes associated with APOE4 in human and APOE knock-in mice and their mitigation with NSAID treatment, through COX-2 inhibition and PPAR-γ activation.
BACKGROUND: Over 70 million Americans inherit the strongest genetic risk factor for Alzheimer's disease (AD), apolipoprotein E4 (APOE4), but have no course for reducing their risk. The association of non-steroidal anti-inflammatory drug (NSAID) use with reduced risk of AD for APOE4-carriers suggests that NSAIDs may be useful in AD prevention. METHODS: We identified phenotypes associated with APOE4 in APOE knock-in mice in order to define modifiable measures that correlate with risk of AD. RESULTS:APOE4mouse brains showed altered post-translational modifications and biochemical distribution of APOE compared to APOE3mice; these differences were also observed in brains of humanAPOE4 carriers. Two-month treatment with ibuprofen significantly altered the expression pattern of APOE in APOE4mice to that of APOE3mice; PPAR-γ agonist pioglitazone also had a significant effect. APOE4mice also show deficits in dendritic spine density, and ibuprofen and pioglitazone significantly increased dendritic spine density. CONCLUSIONS: We report new phenotypes associated with APOE4 in human and APOE knock-in mice and their mitigation with NSAID treatment, through COX-2 inhibition and PPAR-γ activation.
Authors: Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth Journal: Brain Date: 2005-04-07 Impact factor: 13.501
Authors: G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole Journal: J Neurosci Date: 2000-08-01 Impact factor: 6.167
Authors: G W Rebeck; N C Alonzo; O Berezovska; S D Harr; R B Knowles; J H Growdon; B T Hyman; A J Mendez Journal: Exp Neurol Date: 1998-01 Impact factor: 5.330
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Jiang-long Tu; Chong-bo Zhao; Timothy Vollmer; Stephen Coons; Hao-jie Lin; Stephen Marsh; David M Treiman; Jiong Shi Journal: Biochem Biophys Res Commun Date: 2009-05-05 Impact factor: 3.575
Authors: R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander Journal: Neurology Date: 2004-06-08 Impact factor: 9.910
Authors: Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Andrew P Speidell; Tamar Demby; Yichien Lee; Olga Rodriguez; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck Journal: Neurotox Res Date: 2018-10-04 Impact factor: 3.911
Authors: Kristen R Hollinger; Xiaolei Zhu; Elizabeth S Khoury; Ajit G Thomas; Kevin Liaw; Carolyn Tallon; Ying Wu; Eva Prchalova; Atsushi Kamiya; Camilo Rojas; Sujatha Kannan; Barbara S Slusher Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.160